Stephen N Housley
Overview
Explore the profile of Stephen N Housley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
206
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ballarini E, Malacrida A, Rodriguez-Menendez V, Pozzi E, Canta A, Chiorazzi A, et al.
Int J Mol Sci
. 2022 Sep;
23(17).
PMID: 36077454
Oxaliplatin (OHP)-induced peripheral neurotoxicity (OIPN) is a frequent adverse event of colorectal cancer treatment. OIPN encompasses a chronic and an acute syndrome. The latter consists of transient axonal hyperexcitability, due...
12.
Wang A, Housley S, Flores A, Cope T, Perreault E
J Neuroeng Rehabil
. 2022 Mar;
19(1):32.
PMID: 35321749
Background: Oxaliplatin (OX) chemotherapy for colorectal cancer is associated with adverse neurotoxic effects that can contribute to long-term sensorimotor impairments in cancer survivors. It is often thought that the sensorimotor...
13.
Housley S, Nardelli P, Rotterman T, Cope T
Proc Natl Acad Sci U S A
. 2021 Dec;
118(51).
PMID: 34911753
Cancer survivors rank sensorimotor disability among the most distressing, long-term consequences of chemotherapy. Disorders in gait, balance, and skilled movements are commonly assigned to chemotoxic damage of peripheral sensory neurons...
14.
Rotterman T, Carrasco D, Housley S, Nardelli P, Powers R, Cope T
PLoS One
. 2021 Nov;
16(11):e0259918.
PMID: 34797870
The axon initial segment (AIS) responsible for action potential initiation is a dynamic structure that varies and changes together with neuronal excitability. Like other neuron types, alpha motoneurons in the...
15.
Housley S, Rotterman T, Nardelli P, Carrasco D, Noel R, OFarrell L, et al.
Neurotoxicology
. 2021 Aug;
86:162-165.
PMID: 34363843
The persisting need for effective clinical treatment of chemotherapy-induced neurotoxicity (CIN) motivates critical evaluation of preclinical models of CIN for their translational relevance. The present study aimed to provide the...
16.
Wang A, Housley S, Flores A, Kircher S, Perreault E, Cope T
J Neuroeng Rehabil
. 2021 Jan;
18(1):16.
PMID: 33494755
Chemotherapy agents used in the standard treatments for many types of cancer are neurotoxic and can lead to lasting sensory and motor symptoms that compromise day-to-day movement functions in cancer...
17.
Blum K, Campbell K, Horslen B, Nardelli P, Housley S, Cope T, et al.
Elife
. 2020 Dec;
9.
PMID: 33370235
Despite decades of research, we lack a mechanistic framework capable of predicting how movement-related signals are transformed into the diversity of muscle spindle afferent firing patterns observed experimentally, particularly in...
18.
Rich M, Housley S, Nardelli P, Powers R, Cope T
Neuroscientist
. 2020 Dec;
28(2):103-120.
PMID: 33345706
Both sepsis and treatment of cancer with chemotherapy are known to cause neurologic dysfunction. The primary defects seen in both groups of patients are neuropathy and encephalopathy; the underlying mechanisms...
19.
Housley S, Nardelli P, Powers R, Rich M, Cope T
Exp Neurol
. 2020 Jun;
331:113354.
PMID: 32511953
Chemotherapy-induced sensorimotor disabilities, including gait and balance disorders, as well as physical fatigue often persist for months and sometimes years into disease free survival from cancer. While associated with impaired...
20.
Huang K, Leblanc A, Uddin M, Kim J, Chen M, Eisenmann E, et al.
J Clin Invest
. 2020 Jun;
130(9):4601-4606.
PMID: 32484793
Peripheral neurotoxicity is a debilitating condition that afflicts up to 90% of patients with colorectal cancer receiving oxaliplatin-containing therapy. Although emerging evidence has highlighted the importance of various solute carriers...